Experimental virus and immune cell combo targets hard-to-treat melanoma
NCT ID NCT06961786
First seen Mar 19, 2026 · Last updated May 14, 2026 · Updated 6 times
Summary
This early-stage trial tests a new approach for people with advanced melanoma that has not responded to other treatments. It combines a specially designed virus (TILT-123) that targets cancer cells, chemotherapy, and the patient's own immune cells grown in a lab. The main goal is to check if this combination is safe for 9 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Center for Cancer Immune Therapy Herlev Hospital, Copenhagen University
Copenhagen, Denmark
Conditions
Explore the condition pages connected to this study.